Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)
ID: 356499Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356499

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-065.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Novel Therapeutics for Select Fungal Pathogens" under the R21/R33 grant mechanism. This initiative aims to support early-stage translational research focused on drug discovery and development against significant fungal pathogens, including specific species of Candida, Aspergillus fumigatus, Coccidioides, and Mucorales, in response to the urgent need for new antifungal treatments due to rising drug resistance. The program will utilize a milestone-driven approach over two phases, with funding limits of up to $275,000 for the R21 phase (up to two years) and $300,000 annually for the R33 phase (up to three additional years), with an estimated total commitment of approximately $2.4 million for 8-10 projects in fiscal year 2026. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for January 28, 2025.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-065.html
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is encouraging applications for the R21/R33 Phased Innovation Award aimed at discovering and developing novel therapeutics for significant fungal pathogens, including specific Candida species, Aspergillus fumigatus, Coccidioides, and Mucorales. The funding opportunity, identified as RFA-AI-24-065, emphasizes early-stage translational research with milestone-driven support over two phases—R21 (up to two years) and R33 (up to three additional years). The R21 phase focuses on establishing proof-of-concept for potential therapeutics, while the R33 phase will further develop these candidates. The initiative responds to the urgent need for new antifungal treatments due to emerging drug resistance and limited therapeutic options. Eligible applicants include various educational, nonprofit, and governmental organizations, with budget limits set at $275,000 for the R21 phase and $300,000 annually for the R33 phase. The NIH aims to fund 8-10 projects, committing approximately $2.4 million in fiscal year 2026, highlighting the critical priority of addressing fungal infections in public health.
    Similar Opportunities
    Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products," aimed at supporting early-stage translational research for heart, lung, blood, and sleep disorders. This initiative employs a phased approach (R61/R33), where the R61 phase focuses on identifying and validating therapeutic candidates, while the R33 phase involves lead series identification for preclinical testing, emphasizing innovation and addressing therapeutic gaps. The total funding commitment is approximately $4.47 million per fiscal year from 2026 to 2028, with a maximum budget of $400,000 per year for each phase, and applications are due by December 23, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "New Therapeutic Strategies for Genital Herpes" under the R21/R33 Clinical Trial Not Allowed mechanism. This initiative aims to stimulate research into innovative treatments that suppress virus shedding, minimize lesion formation, and reduce transmission risks associated with genital herpes, focusing on the development of new antivirals, therapeutic vaccines, and gene editing technologies. With a total budget of $3.5 million planned to support 7-10 grants, eligible applicants include a wide range of organizations such as academic institutions, nonprofits, and local governments. Interested parties must submit their applications by January 31, 2025, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R21 Clinical Trial Not Allowed), aimed at advancing research in the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between microorganisms, tumors, and the immune system, focusing on their potential to develop innovative strategies for cancer imaging and therapeutics, particularly for solid tumors and oral cancers. The program supports exploratory and developmental research with a maximum budget of $275,000 over two years, encouraging multidisciplinary collaboration to address significant challenges in cancer therapy. Applications are due by May 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at exploring the role of inflammasomes in the context of HIV infection and substance use disorders. This R21 exploratory grant encourages research into the mechanisms of inflammasome activation and their association with neurocognitive disorders in individuals affected by HIV and substance use, with a focus on identifying molecular markers and potential therapeutic innovations. The total funding available is up to $2 million over two years, with applications opening on February 13, 2024, and a submission deadline of March 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at advancing research on the role of inflammasomes in the context of HIV infection and substance use disorders. This initiative seeks to enhance understanding of the mechanisms by which inflammasomes contribute to neuroinflammation and immune dysregulation, with a focus on identifying molecular markers and potential therapeutic targets. Eligible applicants include a diverse range of organizations, such as higher education institutions, community-based organizations, and tribal governments, with funding available up to $500,000 over a two-year project period. The application deadline is March 13, 2025, and interested parties can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.